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AbstrACt
Introduction Patients with advanced cirrhosis have 
enteric bacterial dysbiosis and translocation of bacteria 
and their products across the gut epithelial barrier. This 
culminates in systemic inflammation and endotoxaemia, 
inducing innate immune dysfunction which predisposes 
to infection, and development of complications such 
as bleeding, sepsis and hepatic encephalopathy. This 
feasibility study aims to assess the safety of administering 
faecal microbiota transplantion to patients with cirrhosis 
and explore the effect of the intervention on their 
prognosis by achieving restoration of a healthy gut 
microbiome.
Methods and analysis A PROspective, randomised 
placebo controlled feasibility trial of Faecal mIcrobiota 
Transplantation is a single-centre, randomised, single-
blinded, placebo-controlled study evaluating faecal 
microbiota transplantation (FMT) against placebo. Patients 
with advanced but stable cirrhosis with a Model for End-
Stage Liver Disease score between 10 and 16 will be 
recruited. Twenty-four patients will be randomised to FMT 
plus standard of care (as per our institutional practice) 
and eight patients to placebo in a ratio of 3:1. Patients will 
be evaluated at baseline before the study intervention is 
administered and at 7, 30 and 90 days post-intervention 
to assess safety and adverse events. FMT/placebo will be 
administered into the jejunum within 7 days of baseline. 
The primary outcome measure will be safety and feasibility 
as assessed by recruitment rates, tolerability and safety 
of FMT treatment. Results will be disseminated via peer-
reviewed journals and international conferences. The 
recruitment of the first patient occurred on 23 May 2018.
Ethics and dissemination Research Ethics approval 
was given by the London South East Research Ethics 
committee (ref 17/LO/2081).
trial registration number NCT02862249 and EudraCT 
2017-003629-13.
IntroduCtIon 
Patients with advanced cirrhosis have 
enteric dysbiosis with small bowel bacterial 
overgrowth and translocation of bacteria 
and their products across the gut epithelial 
barrier.1 This culminates in systemic inflam-
mation and endotoxaemia, inducing innate 
immune dysfunction which predisposes to 
infection,2 and development of complications 
such as bleeding, sepsis and hepatic enceph-
alopathy (HE).3 It also plays a key role in the 
natural history of cirrhosis by influencing the 
rate of progression to advanced liver disease 
and terminal liver failure.4 
Using quantitative metagenomics, our group 
has found 75 245 genes differentially expressed 
between patients with cirrhosis and healthy 
individuals. Over 50% of these bacterial species 
are of buccal origin suggesting an invasion of 
the gut from the mouth in cirrhosis.5 Patients 
strengths and limitations of this study
 ► This study is powered to assess feasibility and safe-
ty of administering faecal microbiota transplantation 
(FMT) to patients with cirrhosis, however, it is not 
statistically powered to assess for clinically relevant 
outcomes.
 ► This is the first study examining the effect of FMT 
delivered directly into the small bowel in patients 
with advanced cirrhosis. This trial does not involve 
antibiotic pretreatment in the FMT group, as has 
been undertaken in the USA in patients with hepatic 
encephalopathy.
 ► A PROspective, randomised placebo controlled fea-
sibility trial of Faecal mIcrobiota Transplantation will 
assess instillation of FMT/placebo directly into the 
small bowel, as opposed to the colon, directly tar-
geting small bowel bacterial overgrowth that is ob-
served in cirrhosis.
 ► A limitation of the study is its single-blinded design, 
which was necessary as the FMT and placebo (sa-
line with glycerol) are not matched.
 o
n




pen: first published as 10.1136/bmjopen-2018-023518 on 15 February 2019. Downloaded from 
2 Woodhouse CA, et al. BMJ Open 2019;9:e023518. doi:10.1136/bmjopen-2018-023518
Open access 
with cirrhosis also have salivary dysbiosis associated with 
impaired salivary defences and systemic inflammation. Sali-
vary dysbiosis has been shown to be greater in patients with 
cirrhosis who developed complications necessitating hospi-
talisation within 90 days. Modulating the gut microbiota 
in patients with cirrhosis with the non-absorbable antibi-
otic rifaximin has been associated with improved cognitive 
performance and reduction in endotoxaemia in patients 
with cirrhosis.6 7 Moreover, we have recently performed a 
multicentre retrospective study including 170 patients in 
which rifaximin-α therapy given for 90 days significantly 
(1) reduced hospital readmission rates after 3 months 
treatment, impacting significantly on the National Health 
Service resource burden and (2) reduced overall liver 
disease severity (as measured by the Child Pugh and Model 
for End-Stage Liver Disease (MELD) scores) raising the 
possibility that modulation of gut microbiota may signifi-
cantly modify the natural history of chronic liver failure.8
These data constitute in our view ‘proof of principle’ 
that modifying the gut microbiota in patients with 
cirrhosis improves clinical outcomes. Rifaximin-α was 
approved by National Institute for Health and Care Excel-
lence (NICE) for the prevention of the recurrence of 
overt HE in cirrhosis9 but considerable concern remains 
regarding whether long-term antibiotic prescription will 
result in a change in bacterial function and virulence 
rather than a simple reduction in bacterial population 
and whether this may drive bacterial resistance to anti-
biotics in an already functionally immunocompromised 
population. The question was, therefore, raised as to 
whether directly, as opposed to indirectly modulating 
the gut microbiota using faeces from healthy donors may 
be a safer and more durable therapy. Faecal microbiota 
transplantation (FMT) has been licensed by NICE since 
2014 for the treatment of recurrent Clostridium difficile 
infection.10 FMT has shown promising results in clinical 
trials of several disease states resulting from gut dysbiosis 
beyond C. difficile infection,10 for example, in ulcerative 
colitis.11–14
We hypothesise that in patients with advanced cirrhosis, 
FMT may reduce the progression of chronic liver 
failure including the development of jaundice, ascites, 
bleeding, encephalopathy, infection and organ dysfunc-
tion. Whether FMT is feasible in the setting of cirrhosis 
remains to be investigated. We propose conducting a 
feasibility trial to determine whether FMT from a healthy 




The primary objective of this study will be to assess 
whether stabilising gut dysbiosis with FMT in patients 
with advanced cirrhosis is both feasible and safe.
Primary endpoints
The primary endpoints of the study will be twofold. 
To assess the feasibility of FMT as determined by the 
recruitment rates (including the acceptability of the inter-
vention) and tolerability of FMT, for example, gastro-oe-
sophageal reflux rates. The second primary outcome 
measure will be to assess the safety of FMT administration, 
including the incidence of any transmissible bacterial or 
viral infection that is deemed to have been acquired from 
the donor including C. difficile infection.
secondary objectives
The secondary objectives of the study are to provide 
preliminary evidence of efficacy for a larger randomised 
trial, with the purpose of choosing the optimal primary 
outcome and estimating the parameters for sample size 
calculation. We will also collect blood, saliva, stool and 
urine samples from participants to assess the stability 
of the transplanted gut microbiome by comparing the 
percentage composition of the stool microbiota on day 7, 
30 and 90 with the donor microbiome. Plasma endotoxin 
(and endotoxin binding protein), proinflammatory and 
anti-inflammatory cytokine levels, bacterial DNA quantifi-
cation and serum procalcitonin will be performed at 7, 30 
and 90 days as will changes in faecal biomarkers (calpro-
tectin, lactoferrin and M2-pyruvate kinase).
trial design
A PROspective, randomised placebo controlled feasibility 
trial of Faecal mIcrobiota Transplantation (PROFIT) is a 
single-centre study. Thirty-two patients will be recruited 
from outpatient clinics at King’s College Hospital or from 
box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► 18–75 years.
 ► Confirmed advanced cirrhosis of any aetiology with a Model for End-
Stage Liver Disease15 score between 10 and 16. The diagnosis of 
cirrhosis will be based on clinical, radiological or histological criteria.
 ► Patients with alcohol-related liver disease must have been abstinent 
from alcohol for a minimum of 6 weeks.
 ► Patients must be deemed to have a capacity to consent to the study.
Exclusion criteria
 ► Severe or life-threatening food allergy.
 ► Pregnancy or breast feeding.
 ► Patients treated for active variceal bleeding, infection, bacterial 
peritonitis, overt hepatic encephalopathy or acute-on-chronic liver 
failure within the past 14 days.
 ► Patients who have received antibiotics in the past 14 days.
 ► Active alcohol consumption of >20 g/day.
 ► Has had a previous liver transplant.
 ► Hepatocellular carcinoma outside of the Milan criteria.20
 ► Inflammatory bowel disease.
 ► Coeliac disease.
 ► A history of prior gastrointestinal resection such as gastric bypass.
 ► Patient is not expected to survive the duration of the study (90 days).
 ► Severe renal impairment (creatinine >150 µmol/L).
 ► HIV positive.
 ► Immunosuppression, for example, more than 2 weeks treatment 
with corticosteroids within 8 weeks of intervention, active treatment 
with tacrolimus, mycophenolate, azathioprine.
 o
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suitable inpatients on the wards. The patients will be 
recruited as per the inclusion and exclusion criteria listed 
in box 1. Patients will be randomised in a single-blinded 
fashion in a ratio of 3:1 FMT to placebo. Patients will be 
unaware of the intervention given, but investigators will 
not be blinded to the treatment intervention.
Patient and public involvement
A lay reviewer/patient representative at the National Insti-
tute for Health Research reviewed the protocol. This was 
funded by the Research for Patient Benefit programme. 
Feedback was taken on board and revisions were subse-
quently made.
The British Liver Trust, British Society of Gastroenter-
ology Liver Research Group and King’s Liver Outpatient 
Advisory Group (patient group) were all involved in the 
study set-up and protocol development at all stages.
Results will be disseminated to study participants via the 
Liver Research Nurse if they indicate an interest in the 
study outcome.
Patient population
The study will include all patients aged 18–75 years 
with a capacity to consent and a diagnosis of cirrhosis. 
Patients will have an MELD15 score of between 10 and 
16. The diagnosis of cirrhosis may be based on radiolog-
ical, clinical or histological parameters. In the case of 
alcohol-related cirrhosis, patients must have been absti-
nent for a minimum of 6 weeks. The exclusion criteria are 
outlined in box 2. Anticipated recruitment is outlined in 
figure 1.16
Consent
All participants will be asked to provide informed consent 
after having had the opportunity to discuss the trial with 
the clinician, their family and friends and having read the 
patient information sheet (PIS- see online supplemen-
tary file). Patients who lack capacity will not be enrolled 
in this study. If patients lose capacity during the trial 
follow-up period, an appropriate legal representative will 
be consulted and will provide consent to ongoing trial 
participation after appropriate discussion with the trials 
team and having read the PIS. If the legal representative 
does not agree to ongoing trial participation, the subject 
will be withdrawn from trial follow-up.
study intervention
FMT is prepared in a laboratory at St Thomas’ Hospital 
in accordance with the principles of good manufacturing 
practice and under Manufacturing Authorisation for 
an Investigational Medicinal Product from the Medi-
cines and Healthcare Products Regulatory Agency. FMT 
donors are healthy volunteers with no medical problems 
and normal body mass index. They must not be taking 
Figure 1 Study flow chart and anticipated recruitment. FMT, faecal microbiota transplantation.
 o
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any regular medications and are rigorously screened 
for bloodborne and enteric pathogens prior to dona-
tion. Donors undergo questionnaire screening for risk 
factors at baseline and again at donation to reduce the 
risk of transmissible infection as outlined in box 2 (full 
questionnaire in online supplementary materials). Stool 
is processed (diluted and filtered with the addition of 
glycerol) within 6 hours of donation and stored at −80 
°C for up to 6 months (as previously described).17 Mate-
rial for FMT has full traceability from donor to recipient 
and aliquots of donor stool are kept for 30 years to allow 
further testing in the case of any adverse events. Placebo 
is a solution of saline with glycerol without faecal matter.
Following identification, all patients will attend a 
screening visit and sign the informed consent form. If 
deemed to be eligible, they will attend for a baseline visit 
with full clinical history and examination. Medication 
history will be recorded. Patients will complete a dietary 
questionnaire. Baseline samples of blood, urine, saliva 
and stool will be obtained. All patients will subsequently 
attend for a gastroscopy at which the FMT or placebo 
will be administered under direct visualisation into the 
jejunum via a nasojejunal tube. This will be performed as 
per the local Endoscopy Unit Protocol using topical local 
anaesthetic spray or midazolam sedation as per patient 
preference. Patients will first be asked to take bowel 
preparation to purge the bowel of its native bacteria. This 
consists of two sachets of Moviprep taken prior to gastros-
copy. Patients will be monitored for side effects in the 
Clinical Research Facility after the procedure.
Evaluations during and after treatment
Participants will be reassessed at 7 (±5), 30 (±7) and 90 
(±7) days post-intervention. They will be reviewed in the 
Clinical Research Facility and undergo a physical exam-
ination, review of medications and dietary changes and 
adverse event monitoring. Samples of blood, urine, saliva 
and stool will be taken at these visits also. At the end of 




This feasibility study will evaluate feasibility parameters 
using 95% CIs. The sample size has been proposed mainly 
to enable the trial to be conducted within the allocated 
budget and with acceptable precision for continuous 
outcomes. According to the simulation work by Teare 
et al,18 even with the relatively small pilot sample size of 
20, the planned studies would have at least 80% power 
to detect the target effect size (for continuous outcomes) 
more than 75% of the time. Teare et al recommend that 
60–100 subjects are sufficient to estimate an event rate 
(such as recruitment rates) with acceptable precision in a 
feasibility study, while sample sizes between 24 and 50 have 
been recommended for the accurate estimation of SDs. 
Therefore, we have chosen a sample size of 32 patients 
in this trial to have reliable data on all critical parame-
ters (including event rates) which can also be used when 
planning a larger intervention trial. For event rates (eg, 
recruitment rates) and particularly in the extreme case 
with lower rates, for example, 10%, we estimate a drop of 
precision by only 5% using our updated sample size and 
the minimum recommended by Teare et al (0.16 for 60 
patients vs 0.21 for 32 patients). Figure 2 illustrates the 
reduction in precision of different rates when the sample 
size increases for binary outcomes. This sample size will 
also be feasible within the budget and will provide accept-
able information for planning a future large clinical trial.
The sample size of 32 patients will undergo randomisa-
tion in a 3:1 ratio. This will allow the study to demonstrate 
Figure 2 CI width around one proportion (P) by sample size 
(N) from PASS software V.15.
box 2 blood and stool testing of donor faecal microbiota 
transplantation samples
Blood (serology)
 ► HIV 1+2 serology.
 ► (human T-lymphotrophic virus) HTLV I/II Ab.
 ► Hepatitis A IgG (and if positive IgM).
 ► Hepatitis B surface antigen and core antibody.
 ► Hepatitis C virus antibody.
 ► Hepatitis E.
 ► Syphilis.
 ► cytomegalovirus (CMV)/Epstein Barr Virus (EBV) IgG/M.
 ► Strongyloides stercoralis (ELISA).
Stool
 ► PCR for gastroenteritis agents (Campylobacter, Salmonella, Shigella 
and Escherichia coli O:157).
 ► Ova, cysts and parasites x3.
 ►  Clostridium difficile test.
 ► Norovirus PCR.
 ► Screen for gentamicin and carbapenem-resistant Gram-negative 
organisms.
 ► Screen for methicillin resistant staphylococcus aureus (MRSA).
 ► Helicobacter pylori antigen.
 ► Entamoeba histolytica PCR.
 o
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the feasibility of randomising, yet providing robust 
evidence with respect to the feasibility of the treatment 
and preliminary evidence of efficacy parameters.
The following feasibility criteria have been established:
 ► Twenty-five per cent of screened patients will consent: 
256 patients will allow the estimate of the two-sided 
95% CI of the proportion of consented patients, 
where the distance from the observed proportion to 
the limit is 0.058 units.
 ► Fifty per cent of patients screened will fulfil inclu-
sion/exclusion criteria for the trial: screening 64 
patients will allow the estimate of the two-sided 95% 
CI of the proportion of patients eligible, where the 
distance from the observed proportion to the limit is 
0.128 units.
 ► Eighty per cent of randomised patients will complete 
treatment and follow-up: 26 of 32 patients completing 
will allow the estimate of the two-sided 95% CI for 
a single proportion, where the distance from the 
observed proportion to the limit is 0.177 units.
Differences between the placebo and treatment group 
in efficacy binary outcomes will be estimated along with 
the two-sided 95% CI (table 1). Assuming the proportion 
with the outcome in the control group is 0.5, our sample 
size will allow estimation of the half-width of the CIs for 
different size of differences as indicated below. Differ-
ences of 0.4 or higher will be distinguishable from 0.
Clinical endpoints
Clinical and safety events will be listed and summarised by 
the intervention group. MELD15 scores will be calculated 
by visit and treatment group.
data synthesis, analysis and presentation
Feasibility and efficacy outcomes will be summarised 
using the appropriate descriptive statistics, and 95% CIs 
will be calculated to allow for success and go/no go deci-
sions. Biomarker data will be preprocessed according to 
the established standards for each platform, and statis-
tical analyses will be performed using non-parametric 
and permutation-based methods which are more appro-
priate for small sample sizes.
statistical software
Analyses will be performed using R and/or Stata 
V.14.2 statistical software packages.
dIsCussIon
The PROFIT study is the first study to look at the use of 
FMT delivered directly into the small bowel in patients 
with cirrhosis. Liver transplantation is a highly selec-
tive treatment and only those most likely to benefit 
will be listed. Depending on blood type patients can 
wait up to 24 months for a liver transplant. There are 
even fewer options for patients who are unsuitable for 
transplantation.
Cirrhosis is often complicated by recurrent admissions 
with sepsis, variceal bleeding, ascites and HE. We know 
that patients with cirrhosis have enteric dysbiosis and 
altered gut permeability. The non-absorbable antibiotic 
rifaximin has proved useful in patients with cirrhosis and 
chronic HE, but the long-term benefits of antibiotic use 
are unknown and the possibility of development of bacte-
rial resistance remains with all antibiotics. The possibility 
of repopulating the gut of patients with cirrhosis with 
healthy gut microbiota could be a potential alternative, 
providing a new treatment approach for these vulnerable 
individuals.
A group in the USA have recently published the results 
of the impact of FMT delivered via enema in 10 patients 
with cirrhosis, compared with 10 patients receiving stan-
dard of care treatment.19 FMT was found to be safe and the 
patients in the treatment group did not have any admis-
sions for HE, whereas there were six episodes of HE in the 
standard of care group. Four of these episodes required 
hospital admission. The FMT group were treated with 
broad-spectrum antibiotics prior to FMT administration, 
whereas the standard of care group were not, meaning 
that the effects of FMT cannot be clearly separated from 
the antibiotic administration. We hope that PROFIT will 
add to the knowledge base of the use of FMT in cirrhosis 
and will provide an accurate assessment of the safety of 
FMT. We plan to treat the FMT and control groups identi-
cally, aside from the administration of FMT to accurately 
assess its impact, without the confounding factor of anti-
biotic treatment.
A limitation of our study is the single-blinded design. 
This was selected due to the inherent difficulties in 
preparing a matched placebo, without introducing 
substances that may upset the delicate gut microbiota. 
The IMP will be delivered by the trial investigators, so it 
has not been possible to blind the clinicians in this study. 
Patients and the trial statistician will be blinded.
The study is not powered to detect differences in clin-
ical outcomes, but may provide evidence for markers 
relating to clinical outcomes that could be studied in a 
larger randomised controlled trial.
trial monitoring groups
Trial steering committee
This group will oversee the running of the trial and 
discuss any issues that may arise throughout the process 
of recruitment and follow-up of patients. The group 
will be chaired by an independent clinician. Investi-
gators will report to the group on a regular basis. The 
Table 1 Half-width of CIs for differences in proportions 
between two groups with given sample size, placebo group, 
p=0.5 (created with PASS software REF—PASS V.15)
Difference 0.1 0.2 0.3 0.4 0.5
Width 0.398 0.392 0.382 0.337 0.347
The half-width of the 95% CI of the difference in means for 
continuous outcome will be 0.889 SD.
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data monitoring committee (DMC) will inform the trial 
steering committee (TSC) if there are any issues raised 
from its discussions.
Data monitoring committee
This is an entirely independent group that analyses 
interim data, to determine whether or not the trial is 
safe to continue. It monitors adverse events and adverse 
reactions and reacts to any issues and directs the TSC as 
to whether or not the trial should continue. The DMC 
undertakes interim statistical analysis using an indepen-
dent statistician to ensure the ongoing safety and integrity 
of the trial. The members of this committee are indepen-
dent of the trial, but will be experienced clinicians with 
expertise in clinical trials.
EthICs And dIssEMInAtIon
The results of the trial will be analysed and published in a 
peer-reviewed journal and disseminated at international 
conferences.
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